Miyamoto M, Sugawa H, Mori T, Hase K, Kuma K, Imura H
Second Division of Internal Medicine, Kyoto University School of Medicine, Japan.
Cancer Res. 1988 Jul 1;48(13):3652-6.
Epidermal growth factor (EGF) receptors on primary-cultured human thyroid cells from 27 neoplasias (nine adenomas and 18 differentiated carcinomas) were analyzed and compared with those on the cultured nonneoplastic part of human thyroid cells. Total binding of 125I-EGF to the nonneoplastic part, adenoma, and carcinoma cells did not differ significantly. Scatchard analysis showed that the neoplastic human thyroid cells, like their adjacent nonneoplastic counterparts, consistently possessed EGF receptors with two components. In a paired study of five patients, the association constant of the carcinoma cells' high-affinity component (Ka1) was found to be significantly lower than that of adjacent nonneoplastic thyroid cells (P less than 0.05). Furthermore, a study of the cells from 18 carcinomas revealed that overall their Ka1s (4.15 +/- 0.82 x 10(9) M-1, mean +/- SEM) were significantly lower than those of adenoma cells (10.34 +/- 1.51 x 10(9) M-1, n = 9) and of nonneoplastic cells adjacent to them (8.32 +/- 0.84 x 10(9) M-1, n = 23). The difference in Ka1s for adenoma and nonneoplastic thyroid cells was not statistically significant. The number of receptor sites (Cmax) per cell was not significantly different in any of the three. Incorporation of [3H]thymidine (dThd) increased significantly in all kinds of thyroid cells examined following the addition of 10 nM EGF, and the paired study showed that the size of this increase was not significantly different in neoplastic and adjacent nonneoplastic cells. The addition of 300 microunits/ml of thyroid-stimulating hormone caused a significant increase in dThd incorporation by adenoma cells but not by carcinoma or nonneoplastic cells. Furthermore, combined treatment with EGF and thyroid-stimulating hormone additively promoted adenoma cell growth only. A close inverse relationship was observed between Ka1 and the stimulatory effect of EGF on the dThd uptake in both nonneoplastic thyroid cells and adenoma cells. Carcinoma cells also showed similar profiles, but Ka1 relative to dThd increases were much smaller than the other two.
对来自27例肿瘤(9例腺瘤和18例分化型癌)的原代培养人甲状腺细胞上的表皮生长因子(EGF)受体进行了分析,并与培养的人甲状腺细胞的非肿瘤部分的受体进行了比较。125I-EGF与非肿瘤部分、腺瘤和癌细胞的总结合量无显著差异。Scatchard分析表明,肿瘤性人甲状腺细胞与其相邻的非肿瘤对应细胞一样,始终具有两种成分的EGF受体。在对5例患者的配对研究中,发现癌细胞高亲和力成分(Ka1)的缔合常数显著低于相邻的非肿瘤性甲状腺细胞(P<0.05)。此外,对18例癌组织细胞的研究表明,其总体Ka1s(4.15±0.82×10^9 M-1,均值±标准误)显著低于腺瘤细胞(10.34±1.51×10^9 M-1,n = 9)及其相邻的非肿瘤性细胞(8.32±0.84×10^9 M-1,n = 23)。腺瘤和非肿瘤性甲状腺细胞的Ka1s差异无统计学意义。三种细胞中每个细胞的受体位点数量(Cmax)无显著差异。在加入10 nM EGF后,所有检测的甲状腺细胞中[3H]胸腺嘧啶核苷(dThd)的掺入均显著增加,配对研究表明,这种增加的幅度在肿瘤性和相邻非肿瘤性细胞中无显著差异。加入300微单位/ml促甲状腺激素可使腺瘤细胞的dThd掺入显著增加,但对癌细胞或非肿瘤性细胞无此作用。此外,EGF与促甲状腺激素联合治疗仅能协同促进腺瘤细胞生长。在非肿瘤性甲状腺细胞和腺瘤细胞中,均观察到Ka1与EGF对dThd摄取的刺激作用之间存在密切的负相关关系。癌细胞也表现出类似的情况,但相对于dThd增加的Ka1要比其他两者小得多。